2.40

5.73% 0.13

After Hours: 2.40

Annovis Bio Inc (ANVS)

Overview News Price History Why ANVS Down? Discussions Forecast

Annovis Bio Inc stock is traded at $2.40, with a volume of 720.49K. It is up +5.73% in the last 24 hours and up +2.13% over the past month. Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Previous Close:

$2.27

Open:

$2.3

24h Volume:

720.49K

Relative Volume:

0.95

Market Cap:

$83.15M

Revenue:

Net Income/Loss:

$-28.85M

P/E Ratio:

-1.7117

EPS:

-1.4021

Net Cash Flow:

$-25.62M

1W Performance:

+30.43%

1M Performance:

+2.13%

6M Performance:

+20.60%

1Y Performance:

+66.67%

1-Day Range:

$2.20

$2.42

1-Week Range:

$1.86

$2.42

52-Week Range:

$1.44

$5.50

Annovis Bio Inc Stock (ANVS) Company Profile

Name

Annovis Bio Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

484-875-3192

Address

101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA

Employee

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

ANVS's Discussions on Twitter

Compare ANVS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANVS Annovis Bio Inc	2.40	78.65M	0	-28.85M	-25.62M	-1.4021
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-10-25	Downgrade	D. Boral Capital	Buy → Hold
Oct-25-24	Upgrade	Maxim Group	Hold → Buy
Dec-29-23	Initiated	Canaccord Genuity	Buy
Jul-07-21	Reiterated	Maxim Group	Buy

Annovis Bio Inc Stock (ANVS) Latest News

May 05, 2026

Annovis Bio Publishes Phase 2/3 Alzheimer’s Trial Results - MyChesCo

May 05, 2026

May 01, 2026

Annovis Bio Appoints Accomplished Neuroscientist, Dr. Cheng Fang as VP of Research - TMX Newsfile

May 01, 2026

ANVS Earnings History & Surprises | EPS & Revenue Results | ANNOVIS BIO (NYSE:ANVS) - ChartMill

May 01, 2026

Apr 30, 2026

Annovis Bio | DEF 14A: Definitive information statements - Moomoo

Apr 30, 2026

Annovis Bio (ANVS) seeks approval to expand 2019 equity incentive plan at 2026 meeting - Stock Titan

Apr 30, 2026

Annovis Bio Inc (ANVS)

Annovis Bio Inc Stock (ANVS) Company Profile

Compare ANVS vs VRTX, REGN, ARGX, ALNY, ONC

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

Annovis Bio Inc Stock (ANVS) Latest News

Annovis Bio Publishes Phase 2/3 Alzheimer’s Trial Results - MyChesCo

Annovis Bio Appoints Accomplished Neuroscientist, Dr. Cheng Fang as VP of Research - TMX Newsfile

ANVS Earnings History & Surprises | EPS & Revenue Results | ANNOVIS BIO (NYSE:ANVS) - ChartMill

Annovis Bio | DEF 14A: Definitive information statements - Moomoo

Annovis Bio (ANVS) seeks approval to expand 2019 equity incentive plan at 2026 meeting - Stock Titan

Annovis Bio (ANVS) price target increased by 13.94% to 15.98 - MSN

Annovis Bio reports positive cognition data in early Alzheimer’s trial - Investing.com UK

Annovis Bio reports positive cognition data in early Alzheimer’s trial By Investing.com - Investing.com Australia

Annovis Bio reports positive cognition results in early Alzheimer’s trial By Investing.com - Investing.com Nigeria

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio - The Manila Times

Annovis Bio reports positive cognition results in early Alzheimer’s trial - Investing.com

Annovis drug showed cognition gains in early AD; 80% enrolled in Phase 3 - Stock Titan

Annovis Bio, Inc. (NYSE:ANVS) Sees Significant Increase in Short Interest - MarketBeat

Annovis Bio Announces Transfer of Listing to the New York Stock Exchange - TMX Newsfile

Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease - TMX Newsfile

Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022) - TMX Newsfile

Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences - TMX Newsfile

Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics - TMX Newsfile

Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference - TMX Newsfile

Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022 - TMX Newsfile

Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging - TMX Newsfile

Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference - TMX Newsfile

Traders Buy Large Volume of Annovis Bio Call Options (NYSE:ANVS) - MarketBeat

Annovis Bio Price Target Maintained With a $17.00/Share by Canaccord Genuity - Moomoo

Aug Summary: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn

Malvern company closes $10M offering to extend Alzheimer’s therapy testing - Pennsylvania Business Report -

Fed Watch: Can Annovis Bio Inc disrupt its industry2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn

Retail Trends: Will Annovis Bio Inc benefit from seasonalityPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn

Annovis Bio raises $10M to fund Alzheimer’s drug trial By Investing.com - Investing.com Australia

Annovis Bio highlights buntanetap development in published article - MSN

Annovis secures financing for buntanetap’s NDA submission - The Pharma Letter

Annovis Bio raises $10M to fund Alzheimer’s drug trial - Investing.com

A $10M cash boost puts Annovis on track for an Alzheimer’s drug filing - Stock Titan

Annovis Closes $10 Million Offering, Extending Cash Runway - GlobeNewswire

Annovis Bio Announces $10 Million Underwritten Offering to Advance Alzheimer’s and Parkinson’s Drug Development - Minichart

Annovis Bio Prices Registered Direct Offering to Fund Trials - TipRanks

Annovis Bio Secures ~$10 Million Underwritten Registered Direct Offering With Canaccord Genuity - TradingView

Weekly Trades: Will Annovis Bio Inc. benefit from rising consumer demand2026 Market Trends & Safe Capital Preservation Plans - baoquankhu1.vn

Quarterly Risk: Will Annovis Bio Inc stock hit new highs in YEAR2026 Growth vs Value & Weekly Breakout Watchlists - baoquankhu1.vn

Annovis Bio prices $10M stock offering at $1.90 per share - Investing.com Australia

Annovis Bio (ANVS) launches $10M stock and warrant offering for Phase 3 drug - Stock Titan

Annovis Bio (ANVS) raises ~$10M via 5.26M-share registered direct offering - Stock Titan

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission - Bitget

Form 424B5 Annovis Bio, Inc. - StreetInsider

Annovis Bio stock tumbles 26% on dilutive equity offering By Investing.com - Investing.com India

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Annovis Bio stock tumbles 26% on dilutive equity offering - Investing.com

Anovis Bio Inc stock: $10M raise amid Phase 3 push – what it means for you - AD HOC NEWS

Annovis Bio prices $10M stock offering at $1.90 per share By Investing.com - Investing.com South Africa

Annovis Bio Inc Stock (ANVS) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to ANVS